Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

Hegde, Priti S., Karanikas, Vaios, Evers, Stefan · 2016 · Clinical Cancer Research

Abstract

Clinical trials with immune checkpoint inhibitors have provided important insights into the mode of action of anticancer immune therapies and potential mechanisms of immune escape. Development of the next wave of rational clinical combination strategies will require a deep understanding of the mechanisms by which combination partners influence the battle between the immune system's capabilities to fight cancer and the immune-suppressive processes that promote tumor growth. This review focuses on our current understanding of tumor and circulating pharmacodynamic correlates of immune modulation and elaborates on lessons learned from human translational research with checkpoint inhibitors. Actionable tumor markers of immune activation including CD8+ T cells, PD-L1 IHC as a pharmacodynamic marker of T-cell function, T-cell clonality, and challenges with conduct of trials that ask scientific questions from serial biopsies are addressed. Proposals for clinical trial design, as well as future applications of peripheral pharmacodynamic endpoints as potential surrogates of early clinical activity, are discussed. On the basis of emerging mechanisms of response and immune escape, we propose the concept of the tumor immunity continuum as a framework for developing rational combination strategies. Clin Cancer Res; 22(8); 1865–74. ©2016 AACR. See all articles in this CCR Focus section, “Opportunities and Challenges in Cancer Immunotherapy.”

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-1507

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 86 references

Cited by

See all 1,000

Metadata

Authors
Hegde, P. S., Karanikas, V., & Evers, S.
Affiliations
  • Genentech (US)
  • F. Hoffmann-La Roche AG (CH)
Corresponding author
Hegde, Priti S.
Venue
Clinical Cancer Research
Published
2016-04-14
Volume
22
Issue
8
Pages
1865-1874
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2338576144
Cited by
1,000
References
86
Citations by year
2026: 53 · 2025: 82 · 2024: 93 · 2023: 164 · 2022: 169 · 2021: 137 · 2020: 114 · 2019: 70 · 2018: 58 · 2017: 46 · 2016: 14
FWCI
6.31
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
immune checkpoint inhibitors, cancer immunotherapy, immune monitoring, pharmacodynamic biomarkers, PD-L1 immunohistochemistry, CD8+ T cells, T cell clonality, tumor immune evasion, combination immunotherapy, clinical trial design, serial biopsies, surrogate endpoints
MeSH terms
Animals, Antineoplastic Agents, Biopsy, Humans, Immunologic Surveillance, Neoplasms, Research Design, Time Factors, Biomarkers, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, Immunomodulation, Molecular Targeted Therapy, Costimulatory and Inhibitory T-Cell Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-1507
The paper
Hegde, P. S., Karanikas, V., & Evers, S. (2016). The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-1507

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.